OBJECTIVE: To evaluate the outcome of @entity1 with @entity5 treated with @entity342 ablation plus external-beam radiation therapy. @entity1 AND METHODS: Sixty consecutive @entity1 treated between August 1986 and February 1995 with @entity342 ablation plus radiation therapy for stage IV (T1-4 N1 M0) @entity263 were selected for outcome analysis in this retrospective study. Bilateral pelvic lymphadenectomy was performed in 56 @entity1 (93%). The 4 remaining @entity1 had pelvic @entity3018 on computed tomography, which was confirmed histologically in all @entity1 . The median pretreatment @entity1486 level was 28.8 ng/mL (mean, 55 ng/ mL; range, 0.1-428 ng/mL). All @entity1 received radiation therapy to the prostate, and 29 (48%) had pelvic node radiation. Biochemical failure was defined according to the American Society for Therapeutic Radiology and Oncology criteria of 3 successive increases in the @entity1486 level. RESULTS: The median follow-up duration for surviving @entity1 was 101.1 months (range, 20-134 months). Biochemical failure with (in 2 @entity1 ) or without (in 10 @entity1 ) clinically evident disease relapse was noted in 12 @entity1 (20%). Four additional @entity1 (7%) had clinical relapse without biochemical failure. Local recurrences were observed in 6 @entity1 (10%), and this clinical impression was confirmed by biopsy in 4 @entity1 . Thirteen @entity1 (22%) died of causes related to @entity263 . The biochemical relapse-free, clinical disease-free, overall, and cause-specific survival rates at 5 years were 82%, 84%, 76%, and 80%, respectively. CONCLUSIONS: This observational case series of @entity1 treated with the combination of external-beam radiation therapy and permanent @entity342 ablation for @entity5 suggests that the addition of @entity342 deprivation therapy to radiation therapy may improve disease outcome. In the absence of randomized trial results, these observations may be beneficial in clinical decision making.

@entity263 : evaluation of the results of the combination of XXXX deprivation therapy and radiation therapy.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity263 :: ('MESH:D011471', 'Disease') :: ['adenocarcinoma of the prostate', 'prostate cancer'] @entity3018 :: ('MESH:D009377', 'Disease') :: ['adenopathy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['pathologic stage IV prostate cancer'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen (PSA)', 'PSA']
@entity342 :: (CHEBI:50113,Chemical) :: ['androgen']
